Is Chimerix (NASDAQ:CMRX) In A Good Position To Invest In Growth?

Simply Wall StDec 11 20:06

H.C. Wainwright Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $11

Futu NewsDec 11 19:33 · Ratings

HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target

BenzingaDec 11 19:30 · Ratings

Chimerix Analyst Ratings

BenzingaDec 11 19:28 · Ratings

Edward White's Buy Rating on Chimerix Driven by Promising Clinical Data and Strategic NDA Plans

TipRanksDec 11 19:15 · Ratings

CervoMed CRVO Phase 2b Fails; Chimerix SNDA Application

BioPharmCatalystDec 11 05:10